GHRP-2

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) and potent ghrelin receptor (GHS-R1a) agonist. It occupies a pharmacological middle ground between the strong but appetite-stimulating GHRP-6 and the clean but less potent Ipamorelin. GHRP-2 produces robust GH release comparable to GHRP-6 while generating significantly less appetite stimulation — a compromise that has made it the preferred "balanced" GHRP for many researchers.

GHRP-2 activates the GHS-R1a receptor with high binding affinity, triggering the IP3/calcium-mediated GH release pathway in pituitary somatotrophs. Comparative binding studies show GHRP-2 has higher receptor affinity than GHRP-6, resulting in slightly greater GH release at equivalent doses. Its appetite-stimulating effect is present but moderate — approximately 50-60% of the appetite drive produced by GHRP-6 — because GHRP-2 has a lower ratio of hypothalamic (appetite-driving) versus pituitary (GH-releasing) GHS-R1a activation. GHRP-2 does produce mild, transient elevations in cortisol and prolactin, though these are dose-dependent and clinically insignificant at typical research doses.

Research has documented that GHRP-2 produces acute GH elevations of 7-15 fold above baseline, with concurrent IGF-1 increases of 30-80% over sustained protocols. Comparative studies with other GHRPs consistently rank GHRP-2 as the highest-potency secretagogue when measured by pure GH output per microgram administered. The literature also documents improvements in sleep quality, body composition, muscle recovery, and immune function associated with the sustained GH/IGF-1 elevation produced by GHRP-2 protocols.

GHRP-2 is suited for researchers who want maximal GH output with manageable appetite effects — the researcher who finds Ipamorelin too mild but GHRP-6's appetite drive disruptive. It is an excellent choice for body composition research, recovery optimization, and anti-aging protocols where strong GH stimulation is the priority. Pair with CJC-1295 No DAC for the classic GHRH/GHRP synergy stack.

Reconstitute the 10mg vial with 2-5ml bacteriostatic water. Administer via subcutaneous injection, 100-300mcg per dose, 2-3 times daily. Inject on an empty stomach. A mild appetite increase may occur 15-20 minutes post-injection. Half-life is approximately 20-30 minutes. Store reconstituted solution at 2-8C. The 10mg format provides extensive supply for sustained research protocols.